Effect of Pioglitazone on Ambulatory Blood Pressure

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The anti-diabetic pioglitazone has been found to reduce casual blood pressure. To date, no data are available looking at this effect in detail. Especially, ambulatory blood pressure has not yet been utilized to confirm the hypothesis that pioglitazone has blood pressure lowering effects.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Erlangen-Nürnberg Medical School
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Age 45-75 years

• Diabetes mellitus Type 2 (HbA1c 7 - 8.5%)

• Casual blood pressure > = 130/80 mmHg, < 160/100 mmHg

Exclusion Criteria:

• Therapy with insulin

• Combination therapy of sulfonyl-urea und metformin

• Therapy with nateglinid, repaglinid or an other substance of this drug family

• Allergy against pioglitazone or other composites of the tablet

• History of heart failure (NYHA I bis IV)

• Hepatic insufficiency

• Transaminases > 2.5-fold of the upper normal limit

• End-stage renal failure

• Syndrome of polycystic ovaries

• Absence of effective contraception in women of childbearing potential

• Pregnancy or breast-feeding